Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
Open Access
- 30 December 2022
- journal article
- research article
- Published by MDPI AG in Metabolites
- Vol. 13 (1) , 58
Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative haematological malignancy characterized by constitutive activation of BCR-ABL1 tyrosine kinase in the majority of patients. BCR-ABL1 expression activates signaling pathways involved in cell proliferation and survival. Current treatment options for CML include tyrosine kinase inhibitors (TKI) with resistance as a major issue. Various treatment options for overcoming resistance are being investigated. Among them, phytochemical curcumin could play an important role. Curcumin has been found to exhibit anti-cancerous effects in various models, including CML, through regulation of multiple molecular signaling pathways contributing to tumorigenesis. We have evaluated curcumin’s effects on imatinib-sensitive LAMA84S and K562, as well as imatinib-resistant LAMA84R cell lines. Our results indicate a significant dose-dependent decrease in cell viability and proliferation of imatinib-sensitive and imatinib-resistant cell lines after curcumin treatment. Suppression of key signaling molecules regulating metabolic and proliferative events, such as Akt, P70S6K and NF-kB, was observed. Increased expression of caspase-3 suggests the potential pro-apoptotic effect of curcumin in the imatinib-resistant CML model. Additional in silico molecular docking studies revealed binding modes and affinities of curcumin with different targets and the results are in accordance with in vitro findings. Altogether, these results indicate the potential role of curcumin in the treatment of CML.Keywords
Funding Information
- Collaborative Research Programme (CRP)—International Centre for Genetic Engineering and Biotechnology (ICGEB) (CRP/BIH15-05)
This publication has 69 references indexed in Scilit:
- Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem CellsStem Cells International, 2013
- Management of imatinib-resistant patients with chronic myeloid leukemiaTherapeutic Advances in Hematology, 2012
- Potential of the Dietary Antioxidants Resveratrol and Curcumin in Prevention and Treatment of Hematologic MalignanciesMolecules, 2010
- Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?Seminars in Hematology, 2010
- Structural Basis of Human p70 Ribosomal S6 Kinase-1 Regulation by Activation Loop PhosphorylationJournal of Biological Chemistry, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- CURCUMIN: THE INDIAN SOLID GOLD2007
- A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculationsJournal of Computational Chemistry, 2003
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Structure of an IκBα/NF-κB ComplexCell, 1998